Skip to main content
Download PDF

The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis

European Journal of Medical Research volume 28, Article number: 39 (2023) Cite this article

Abstract

Background

Primary central nervous system (CNS) tumors are a heterogeneous group of neoplasms, including benign and malignant tumors. Since there are many heterogeneities in the prevalence reported in previous studies on this type of tumor, this study was performed to determine the overall prevalence of different primary CNS tumors.

Method

The study was conducted as a systematic review and meta-analysis by searching international databases, including PubMed, Scopus, Science Direct, Web of science, and the Google Scholar search engine until August 2020. After transferring the studies to information management software (EndNote) and eliminating duplicate studies, the remaining studies were reviewed based on inclusion and exclusion criteria according to three stages of primary and secondary evaluation and qualitative evaluation. Comprehensive Meta-Analysis software, Begg, Mazumdar, and I2 tests were used for data analysis, publication bias analysis, and heterogeneity analysis, respectively.

Results

After performing the systematic review steps, 80 studies were included for final analysis. Based on 8 studies, the prevalence of brain tumors was 70.9%. Also, studies on 7 other studies showed that the prevalence of spinal tumors was 12.2%. A review of 14 studies showed that the prevalence of neuroepithelial tumors was 34.7%. The analysis of 27 studies reported a prevalence of glioma tumors of 42.8%. Analyses performed on other studies showed that the prevalence of pituitary adenomas was 12.2%, embryonal tumors 3.1%, ependymal tumors 3.2%, meningiomas 24.1%, glial tumors 0.8%, astrocytic 20.3%, oligodendroglial 3.9%, glioblastoma 17.7%, schwannoma 6.7%, medulloblastoma 7.7% and Polycystic astrocytomas 3.8%.

Conclusion

As a result, it can be stated that brain tumors are the most common type of primary CNS tumors. It was also observed that tumors involving neuroepithelial cells are more common in patients than other types of tumors.

Related studies

Studies in the field of primary central nervous system tumors are broad, and so far, no study has collected data from these extensive studies. Certainly, determining the general prevalence of nervous system tumors can make policy measures in the prevention, diagnosis, and treatment of tumors effective and reduce treatment costs.

Background

Primary tumors of the central nervous system (CNS) are a heterogeneous group of neoplasms that include benign and malignant tumors [1], which are known as tumors in the brain and spinal cord [2]. Various factors such as age, race, ethnicity, gender, environmental factors, hormones, and genetics can play a role in the etiology of CNS tumors [3]. More than 100 types of tumors that are histologically different are known as subtypes of CNS tumors. The incidence of each tumor varies with age and tissue involved. These tumors include glioma, astrocytoma, embryonal tumors, meningioma, and medulloblastoma [4]. Pituitary and pineal gland tumors are other CNS tumors [2]. The most common malignant tumor among CNS tumors is glioblastoma which has the highest mortality rate. On the other hand, meningioma is known as the most common benign tumor [5].

CNS tumors are not as common as other tumors, such as gastrointestinal cancers. However, the number of people with CNS tumors has increased over time [6]. CNS tumors are the most common type of cancer and the second leading cause of death at the age of 19 in the United States and Canada [7].

A 2020 study of 242 Indian children found that boys were more likely to be infected than girls. This study stated that the cerebellum was the most common site of tumors in the studied samples, followed by the brain’s hemispheres with the highest incidence of tumors [8].

Generally, primary malignancies account for about 2% of all cancers. About half of CNS tumors are benign. However, if benign tumors are not operable and radiotherapeutic, they can be fatal due to growth in the closed space of the skull [9]. A population-based study in 2019 stated that 5.5 out of 100.00 people develop glioma [10]. Another study in Iran stated that 6 out of 100,000 people are diagnosed with CNS tumors [11].

CNS tumors are recognized as one of the leading causes of death in children and adults [12]. In a way, these tumors are the second leading cause of death in children and the third leading cause of death in adults [9]. Also, the complications of this disease have a great impact on the individual, family, and social lifestyle of patients [13].

CNS tumors increase the pressure inside the skull or the spinal cord by stimulating or destroying adjacent nerve tissue and spreading the mass in a constant volume, which causes symptoms. A histological type of CNS tumor may show different clinical symptoms depending on the anatomical location involved. Therefore, it seems difficult to diagnose the exact type of tumor and its malignancy based on clinical signs [14].

There are several factors associated with CNS tumors that should be considered, including the choice of a new and appropriate biological treatment method and the effect of the natural history of brain development on the nature of the disease [13]. CNS tumors can cause mental alteration and neurological disorders and put a heavy burden on families and the health system [2].

Because CNS tumors are very diverse and cause different complications in different people and cause severe disabilities in a person, early diagnosis of tumor type is very important. Also, since there is a lot of heterogeneity due to previous studies on this type of tumor, the present study is conducted to investigate the prevalence of different types of primary CNS tumors.

Method

Protocol and information resources

This study was performed by systematic review method and following PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) [15], and it examines the prevalence of primary CNS tumors worldwide. The search was conducted in the following databases up to 29 August 2020: PubMed, Scopus, Science Direct, and Web of science (WoS).

Search strategy

Initially, a comprehensive study was conducted to select appropriate terms around the title. After selecting keywords appropriate to this systematic review study, a search was conducted in the databases. To access the articles, the keywords; central nervous system tumors, primary brain tumors, spinal cord neoplasm, glioma, meningioma, glioblastoma, oligodendroglioma, medulloblastoma, astrocytoma, prevalence, cross-sectional, and outbreak were used. The articles were collected in Endnote software after performing the search without any time limit. To maximize the search comprehensiveness, the list of sources used in all related articles found in mentioned search was manually reviewed.

Inclusion and exclusion criteria of the study

The inclusion and exclusion criteria of this study were designed based on PICOS guidelines. Inclusion criteria for this study included: 1- studies that examined the prevalence of primary CNS tumors, 2- observational studies, and 3- cross-sectional studies. Exclusion criteria included: 1- unrelated study, 2- studies without sufficient data, 3- duplication studies, 4- unclear study methods, 5- interventional studies, 6- case report studies, and 7- studies for which the full text is not available.

Selection and extraction of studies

After transferring all the extracted studies to EndNote software, duplicate articles that were identified were removed. the researchers reviewed the studies by title and abstract by the defined inclusion and exclusion criteria. during the second evaluation process, the full text of the remaining articles was re-examined based on the inclusion and exclusion criteria. During these steps, studies were performed by two researchers independently to minimize bias. If there was a disagreement between the two researchers, the studies were conducted by a third party. After these steps, the approved studies entered the qualitative evaluation stage to evaluate the methodological quality. Information on all final articles submitted to the systematic review and meta-analysis process is extracted from a pre-prepared checklist. This checklist the included article title, first author name, year of publication, place of study, sample size, sample evaluation method, gender, type of study, study population, number of people with CNS tumors in general, and the tumor type.

Qualitative evaluation of studies

Since cross-sectional observational studies were considered the inclusion criteria, the STROBE checklist was used to critique and evaluate the quality of articles approved in the previous stages. This checklist has 22 items, some of which have several sections, so the STROBE checklist contains a total of 32 items that examine different parts of the study body, including the title, abstract, introduction, data collection methods, statistical analysis methods, and presentation of results. Articles that have lost more than 50% of the items defined in the STROBE checklist are considered as poor quality articles due to their high probability of bias and were excluded from the study, so at this stage, studies that were considered qualitatively as studies of good and average methodological quality entered the analysis process. In the present study, based on the evaluation made based on the STROBE checklist, 78 articles were entered into the systematic review and meta-analysis process as good and medium methodological quality studies.

Statistical analysis

The I2 test was used to evaluate the heterogeneity of the selected studies. To investigate the dissemination error due to the high volume of samples included in the study, the Egger test was applied at a significant level of 0.05 and the corresponding funnel plot. Data analysis was performed using Comprehensive Meta-Analysis software (Version 2).

Results

In this systematic review and meta-analysis study, the information of studies conducted about the prevalence of primary central nervous system (CNS) tumors in the world until 29 August 2020 was systematically reviewed according to PRISMA guidelines. Based on the initial search in the database, 2186 possible related articles were identified and transferred to the information management software (EndNote). 535 out of 2186 identified studies were duplicated and excluded. In the screening phase, out of 1651 studies, the remaining 1513 articles were removed by studying the titles and abstracts based on inclusion and exclusion criteria. In the competency evaluation stage, out of 138 studies, the remaining 60 articles were removed by studying the full text of the article based on inclusion and exclusion criteria due to irrelevance. In the qualitative evaluation stage, all 80 studies were confirmed by reading the full text of the article and based on the score obtained from the STROBE checklist (Fig. 1; Table 1).

Fig. 1
figure 1

Flowchart of PRISMA

Full size image
Table 1 Information of articles
Full size table

Pituitary adenomas

26 studies with a sample size of 331,575 people working on pituitary adenomas were obtained, which its highest prevalence reported by Gittleman et al. [16]. In contrast, the lowest prevalence was reported by Stiller et al. [17] (Table 1). Based on the analysis (I2: 99.6) and publication results bias of Begg and Mazumdar rank correlation test analysis at a significance level of 0.1, heterogeneity of the study was not significant (p: 0.566) Meta-analysis, according to which the prevalence of pituitary adenomas was 12.2 (95% CI 9.4–15.7) (Table 2).

Table 2 Heterogeneity, publication bias, and the overall prevalence of tumors studied in the study based on meta-analysis and random analysis
Full size table

Glioma

In the study of glioma tumors, 27 studies with a sample size of 303,967 people were obtained. The highest prevalence of which was reported by Christensen et al. [18], and the lowest prevalence by Semher et al. [19] (Table 1). The heterogeneity of the study was not significant according to the analysis (I2 99.9) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 (p: 0.113). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to the prevalence of glioma tumor, which was 42.8 (95% CI: 29–57.7) (Table 2).

Embryonal tumors

In the study of embryonal tumors, 14 studies with a sample size of 207,577 people were obtained, the highest prevalence of which was reported by Bauchet et al. [20]; however, the lowest prevalence was reported by Gigineishvili et al. [21] (Table 1). Based on analysis (I2: 99.3) and the results of diffusion bias according to the Begg and Mazumdar rank correlation test analysis at a significance level of 0.1, the heterogeneity of the study was not significant (p: 0.742). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of embryonal tumors was 3.1 (95% CI: 2.1–4.5) (Table 2).

Ependymal tumors

33 studies with a sample size of 379,800 people were obtained working on ependymal tumors, showing the highest prevalence of which was reported by Schlinger et al. [22] and the lowest prevalence by Jiginishvili et al. [21] (Table 1). A study of the heterogeneity of these researches showed the result was insignificant (p: 0.258) based on analysis (I2: 99.7) and diffusion bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of ependymal tumors was 3.2 (95% CI: 2.3–4.4) (Table 2).

Meningioma

In the study of meningioma tumors, 42 studies with a sample size of 450,109 were obtained. The highest prevalence of which was reported by Dolesk et al., [23], and the lowest prevalence by Katesh et al. [24] (Table 1). The heterogeneity study of the reports was insignificant (p: 0.438) according to the analysis (I2: 99.7) and diffusion bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of meningioma was 24.1 (95% CI: 20.5–28.1) (Table 2).

Glial tumor of CNS and pineal gland

In the study of glial tumors of CNS and pineal gland, 17 studies with a sample size of 228,500 people were obtained, showing the highest prevalence of which was reported by Lim Soo et al. [25], and the lowest prevalence was reported by Lim Soo et al. [25] (Table 1). Investigation of heterogeneity in the studies was not significant (p: 0.692), based on analysis (I2: 99.4) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of astrocytic tumors of the CNS was 0.8 (95% CI: 0.4–1.5) (Table 2).

Astrocytic tumors of CNS

In the study of astrocytic tumors of the CNS, 33 studies were obtained with a sample size of 375,302 people, demonstrating the highest prevalence of which was reported by Croust et al. [26]. In contrast, the lowest prevalence was reported by Jesual et al. [27] (Table 1). A study of the heterogeneity of the research showed the result was not significant (p: 0.744), based on analysis (I2: 99.9) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in studies of the random-effects model, Meta-analysis was used, according to which the prevalence of astrocytic tumors of the CNS was 20.3 (95% CI: 15–26.8) (Table 2).

Oligodendroglial

In the study of the oligodendroglial tumor, 34 studies with a sample size of 387,350 people were obtained, the highest prevalence of which was reported in the study of Nielsen et al. [28] and the lowest prevalence in the study of Poschio et al. [29] (Table 1). Based on analysis (I2: 99.5) and publication bias results according to Begg and Mazumdar rank correlation test analysis at a significance level of 0.1, it was shown that heterogeneity of these studies was not significant (p: 0.802). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of oligodendroglial tumor was 3.9 (95% CI: 3.1–4.9) (Table 2).

Choroid plexus

In the study of choroid plexus tumors, 16 studies with a sample size of 219,897 people were obtained, the highest prevalence of which was reported by Basht et al. [20], and the lowest prevalence was reported by Caldarella et al. [30] (Table 1). Study heterogeneity of the reports revealed no significant result (p: 0.444) based on analysis (I2: 98.5) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of choroid plexus tumor was 0.4 (95% CI: 0.2–0.7) (Table 2).

Tumors of neuroepithelial tissue

In the study of tumors of neuroepithelial tissue, 14 studies with a sample size of 162,538 people were obtained, the highest prevalence of which was reported by Luna et al. [31], and the lowest prevalence was reported by Jiginishvili et al. [21] (Table 1). Based on analysis (I2: 99.8) and publication bias results obtained by Begg and Mazumdar rank correlation test analysis at a significance level of 0.1, investigation of the heterogeneity showed no significant data (p: 0.324). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of tumors of neuroepithelial tissue was 34.7 (95% CI: 28.6–41.3) (Table 2).

Glioblastoma

In the study of glioblastoma tumors, 26 studies with a sample size of 616,726 people were obtained, showing the highest prevalence of which was reported by Davis et al. [32] and the lowest prevalence was reported by Desandes et al. [33] (Table 1). Study heterogeneity based on analysis (I2: 99.9) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significant result (p: 0.133). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of glioblastoma tumor was 17.7 (95% CI: 13.9–22.3) (Table 2).

Germ cell tumors

In the study of germ cell tumors, 16 studies were obtained with a sample size of 104,207 people, revealing the highest prevalence of which was reported by Lee et al. [34] and the lowest prevalence by Calderla et al. [30] (Table 1). The heterogeneity of the study was not significant (p: 0.115) based on analysis (I2: 99.7) and results of publication bias based on the analysis of the Begg and Mazumdar rank correlation test at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of germ cell tumors was 2.6 (95% CI: 0.8–8.2) (Table 2).

Brain tumor

In the study done on a brain tumor, 8 studies with a sample size of 314,938 people were obtained, revealing the highest prevalence of which was reported by Ghader et al. [35] and the lowest prevalence was reported by Lee et al. [34] (Table 1). Study heterogeneity based on analysis (I2: 99.2) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 0.710). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of brain tumors was 70.9 (95% CI: 63.1–77.5) (Table 2).

Spinal tumor

In the study performed on the spinal tumor, 7 studies with a sample size of 108,524 people were obtained, the highest prevalence of which was reported by Schillinger et al. [22], and the lowest prevalence was reported by Johansen et al. [36] (Table 1). Study heterogeneity based on analysis (I2: 99.9) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 1.000). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of spinal tumor was 12.2 (95% CI: 5–27.1) (Table 2).

Schwannoma

In the study of schwannoma tumor, 6 studies with a sample size of 65,400 people were obtained, showing the highest prevalence of which was reported by Preston et al. [37] and the lowest prevalence by Basht et al. [20] (Table 1). Study heterogeneity based on analysis (I2: 93.3) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 0.259). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis to determine the prevalence of schwannoma tumor was 6.7 (95% CI: 5.3–8.4) (Table 2).

Medulloblastoma

In the study performed on medulloblastoma tumor, 19 studies with a sample size of 172,593 people were achieved, showing the highest prevalence of which was reported by Small et al. [38] and the lowest prevalence was reported by Nakamura et al. [39] (Table 1). Study heterogeneity based on analysis (I2: 99.6) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 0.093). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of medulloblastoma was 7.7 (95% CI: 4.2–13.6) (Table 2).

Pilocytic astrocytomas

In the study done on pilocytic astrocytomas, 16 studies with a sample size of 427,683 people were obtained, clarifying the highest prevalence of which was reported by Burkard et al. [40] and the lowest prevalence was reported by Doo et al. [41] (Table 1). Study heterogeneity based on analysis (I2: 99.7) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 0.162). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of pilocytic astrocytomas was 3.8 (95% CI: 2.3–6.5) (Table 2).

Discussion

In the present study, the prevalence of primary tumors was investigated worldwide by systematic review and meta-analysis using 78 studies. In his review study, it was found that the highest prevalence of brain tumors is 70.9%. Afterward, neuroepithelial, glioma, meningioma, and glioblastoma tumors have the most significant prevalence, respectively, while finally, medulloblastoma, schwannoma, pilocytic astrocytomas, and oligodendroglial have the least prevalence. The choroid plexus has also the lowest prevalence among primary tumors. In a study conducted by Tamimi et al., In Jordan, the astrocytic glioma tumor was identified as the most common primary tumor, with a prevalence of 37.7% [47]. However, in our study, tumor type was measured as two separate tumors, which ultimately showed that glioma tumors have a prevalence of 31.9% and astrocytic tumors of 21%, which is almost similar to the data obtained from the study done by Tamimi et al. Another study by Johansen et al., it was considered that brain tumors are the most common primary tumors [36] which in our study brain tumors were also measured as the most common primary tumors. In another study by Poschio et al., meningioma and glioblastoma were identified as the most common, with a prevalence of 35% and 26.9%, respectively [29].

Konsel et al. conducted a study to measure the incidence of intracranial tumors in Latin Scotland between 1990 and 1989, which identified 228 primary tumors and 214 secondary tumors. Among the 228 primary tumors, neuroepithelial tumors, which include astrocystic, oligodendroglia, mixed glioma, ependymoma, pineal, and embryonic, were observed in 122 patients (53.5%). Therefore, neuroepithelial tumors were recognized as the most common tumors. Germ cell tumors also showed the lowest prevalence (0.4%). The prevalence study of neuroepithelial tumors is slightly different from our data (34.7%). Our study also presents the lowest prevalence for choroid plexus tumor whose prevalence has not been measured by Consell et al. study [93].

According to studies reported in South Korea, Norway, China, and Jordan, the prevalence of brain tumors was 35, 60.2, 24.56, and 4.4, respectively, which is almost consistent with the results obtained by our study. In most of these studies, brain tumors have a significant prevalence [34,35,36, 79]. Another primary tumor that had a high prevalence in our study was neuroepithelial tumors which were almost consistent with the previously reported results [25, 29, 53, 54]. It was also observed that the prevalence of choroid plexus tumors is consistent with the present study [47, 67].

It has been observed that the prevalence of primary tumors is increasing in some European countries. Various environmental reasons have been put forward for including, including ionizing radiation, some serum compounds such as N nitrous compounds, air pollution, radio spectrum of electromagnetic waves, and ionizing radiation of the brain, which are among the environmental factors increasing the risk of central nervous system primary tumors. Given the industrial nature of the countries, this seems logical. [94] Among non-European countries, Japan also has a significant prevalence of primary tumors due to radiation from the atomic bomb. In one study, schwannoma was the most common tumor in this country [37], and meningioma was identified as the most common primary tumor in the country [39], showing the important impact of environmental factors on the incidence of central nervous system primary tumors.

Among the cases that measured the prevalence according to age and sex, we can mention the study of Martin Preston, in which it was found that the prevalence of primary tumors is higher in women [65]. A study by Joannstrand et al. found that the prevalence of pituitary tumors in women was higher than in men [43]. Prevalence concerning age has been reported in almost similar studies, and those studies have shown that these tumors are more prevalent in middle-aged people [21, 50, 54, 58].

Limitation

One of the limitations of this study is the lack of access to data related to age and gender. Also, the lack of access to full text in some studies was another limitation observed in this study.

Conclusion

As a result, it can be stated that brain tumors are the most common type of primary CNS tumors. It was also observed that tumors involving neuroepithelial cells are more common than other tumors. Since environmental factors are known to be among the factors affecting the prevalence of these tumors, it is necessary to measure the discriminant effect of each of these factors on the prevalence of primary CNS tumors in future studies.

Availability of data and materials

Datasets are available through the corresponding author upon reasonable request.

Abbreviations

SID:

Scientific Information Database

MESH:

Medical Subject Headings

WoS:

Web of Science

PRISMA:

Preferred Reporting Items for Systematic Reviews and Meta-Analysis

STROBE:

Strengthening the reporting of observational studies in epidemiology for cross-sectional study

CNS:

Primary central nervous system

References

  1. Materljan E, et al. Epidemiology of central nervous system tumors in Labin area, Croatia, 1974–2001. Croat Med J. 2004;45(2):206–12.

    Google Scholar 

  2. Lee C-H, et al. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010;48(2):145.

    Article  Google Scholar 

  3. Liigant A, et al. Epidemiology of primary central nervous system tumors in Estonia. Neuroepidemiology. 2000;19(6):300–11.

    Article  CAS  Google Scholar 

  4. Bauchet L, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol. 2008;92(1):87.

    Article  Google Scholar 

  5. Prados MD, Berger MS, Wilson CB. Primary central nervous system tumors: advances in knowledge and treatment. CA Cancer J Clin 1998; 48(6): 331–60, 321.

  6. Chen L, et al. Central nervous system tumors: a single center pathology review of 34,140 cases over 60 years. BMC Clin Pathol. 2013;13(1):14.

    Article  Google Scholar 

  7. Johnson KJ, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomark Prev. 2014;23(12):2716.

    Article  Google Scholar 

  8. Mehta DP, et al. Demographic and histopathologic profile of pediatric patients with primary brain tumors attending a regional cancer center. Indian J Med Paediatr Oncol. 2019;40(5):65.

    Google Scholar 

  9. Buckner JC, et al. Central nervous system tumors. Mayo Clin Proc. 2007;82(10):1271–86.

    Article  Google Scholar 

  10. Ryan CS, et al. Long-term incidence of glioma in Olmsted County, Minnesota, and disparities in postglioma survival rate: a population-based study. Neuro-Oncol Pract. 2020;7(3):288–98.

    Article  Google Scholar 

  11. Malekpourafshar R, et al. The glioblastoma multiforme in Kerman-Iran, 1994–2004. 2006.

  12. de Robles P, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015;17(6):776–83.

    Article  Google Scholar 

  13. Walker D, et al. Central nervous system tumors. In: Cancer in adolescents and young adults. Springer; 2017. p. 335–81.

    Chapter  Google Scholar 

  14. Schoenberg BS. The epidemiology of central nervous system tumors. In: Oncology of the nervous system. Springer; 1983. p. 1–29.

    Google Scholar 

  15. Moher D, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

    Article  Google Scholar 

  16. Gittleman H, et al. Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. J Neurosurg. 2014;121(3):527–35.

    Article  Google Scholar 

  17. Stiller CA, et al. Incidence of childhood CNS tumours in Britain and variation in rates by definition of malignant behaviour: population-based study. BMC Cancer. 2019;19(1):1–15.

    Article  Google Scholar 

  18. Christensen HC, Kosteljanetz M, Johansen C. Incidences of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery. 2003;52(6):1327–34.

    Article  Google Scholar 

  19. Sehmer EA, et al. Incidence of glioma in a northwestern region of England, 2006–2010. Neuro Oncol. 2014;16(7):971–4.

    Article  Google Scholar 

  20. Bauchet L, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol. 2009;92(1):87–98.

    Article  Google Scholar 

  21. Gigineishvili D, et al. Incidence rates of the primary brain tumours in Georgia–a prospective population-based study. Bull Georg Natl Acad Sci 2013; 7(2).

  22. Schellinger KA, et al. Descriptive epidemiology of primary spinal cord tumors. J Neurooncol. 2008;87(2):173–9.

    Article  Google Scholar 

  23. Dolecek TA, et al. Epidemiology of meningiomas post-Public Law 107–206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer. 2015;121(14):2400–10.

    Article  Google Scholar 

  24. Kaatsch P, et al. Population-based epidemiologic data on brain tumors in German children. Cancer Interdiscip Int J Am Cancer Soc. 2001;92(12):3155–64.

    CAS  Google Scholar 

  25. Suh Y-L, et al. Tumors of the central nervous system in Korea a multicenter study of 3221 cases. J Neurooncol. 2002;56(3):251–9.

    Article  Google Scholar 

  26. Crocetti E, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48(10):1532–42.

    Article  Google Scholar 

  27. Jaiswal J, et al. Spectrum of primary intracranial tumors at a tertiary care neurological institute: a hospital-based brain tumor registry. Neurol India. 2016;64(3):494.

    Article  Google Scholar 

  28. Nielsen MS, et al. Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro Oncol. 2009;11(3):311–7.

    Article  Google Scholar 

  29. Pouchieu C, et al. Increasing incidence of central nervous system (CNS) tumors (2000–2012): findings from a population based registry in Gironde (France). BMC Cancer. 2018;18(1):1–13.

    Article  Google Scholar 

  30. Caldarella A, Crocetti E, Paci E. Is the incidence of brain tumors really increasing? A population-based analysis from a cancer registry. J Neurooncol. 2011;104(2):589–94.

    Article  Google Scholar 

  31. Lona C, et al. Incidence of primary intracranial tumors in the province of Bolzano 1980–84. Ital J Neurol Sci. 1988;9(3):237–41.

    Article  CAS  Google Scholar 

  32. Davis FG, et al. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001;3(3):152–8.

    CAS  Google Scholar 

  33. Desandes E, et al. Incidence and survival of children with central nervous system primitive tumors in the French National Registry of Childhood Solid Tumors. Neuro Oncol. 2014;16(7):975–83.

    Article  Google Scholar 

  34. Lee SH, et al. Nationwide population-based incidence and survival rates of malignant central nervous system germ cell tumors in Korea, 2005–2012. Cancer Res Treat. 2017;49(2):494.

    Article  Google Scholar 

  35. Khader YS, et al. The epidemiology and trend of cancer in Jordan, 2000–2013. J Cancer Epidemiol. 2018;2018:1–7.

    Article  Google Scholar 

  36. Johannesen T, et al. Trends in incidence of brain and central nervous system tumors in Norway, 1970–1999. Neuroepidemiology. 2004;23(3):101–9.

    Article  CAS  Google Scholar 

  37. Preston DL, et al. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst. 2002;94(20):1555–63.

    Article  CAS  Google Scholar 

  38. Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19(11):1541–4.

    Article  Google Scholar 

  39. Nakamura H, et al. Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto prefecture in southern Japan—20-year study. Int J Clin Oncol. 2011;16(4):314–21.

    Article  Google Scholar 

  40. Burkhard C, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg. 2003;98(6):1170–4.

    Article  Google Scholar 

  41. Dho Y-S, et al. An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat. 2017;5(1):16.

    Article  Google Scholar 

  42. Ghosh A, et al. The first cross sectional survey on intracranial malignancy in Kolkata, India: reflection of the state of the art in Southern West Bengal. Asian Pac J Cancer Prev. 2004;5(3):259–67.

    Google Scholar 

  43. Tjörnstrand A, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur J Endocrinol. 2014;171(4):519–26.

    Article  Google Scholar 

  44. Daly AF, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769–75.

    Article  CAS  Google Scholar 

  45. Veerasarn K, Yuthagovit S, Chailorrat A. Prevalence of brain tumor in Thailand from 2005 to 2014: data from the National Health Security Office. J Med Assoc Thai. 2016;99(Suppl 3):S62–73.

    Google Scholar 

  46. Radhakrishnan K, et al. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995;37(1):67–73.

    Article  CAS  Google Scholar 

  47. Tamimi AF, et al. Epidemiology of malignant and non-malignant primary brain tumors in Jordan. Neuroepidemiology. 2015;45(2):100–8.

    Article  Google Scholar 

  48. Kurland LT, et al. The incidence of primary intracranial neoplasms in Rochester, Minnesota, 1935–1977. Ann N Y Acad Sci. 1982;381(1):6–16.

    Article  CAS  Google Scholar 

  49. Choi NW, Schuman LM, Gullen WH. Epidemiology of primary central nervous system neoplasms: I. Mortality from primary central nervous system neoplasms in Minnesota. Am J Epidemiol. 1970;91(3):238–59.

    Article  CAS  Google Scholar 

  50. Gigineishvili D, et al. Primary brain tumour epidemiology in Georgia: first-year results of a population-based study. J Neurooncol. 2013;112(2):241–6.

    Article  Google Scholar 

  51. Arora RS, et al. Age–incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol. 2009;11(4):403–13.

    Article  Google Scholar 

  52. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377–82.

    Article  Google Scholar 

  53. D’Alessandro G, et al. Epidemiology of primary intracranial tumors in the Valle d’Aosta (Italy) during the 6-year period 1986–1991. Neuroepidemiology. 1995;14(3):139–46.

    Article  CAS  Google Scholar 

  54. Darlix A, et al. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017;131(3):525–46.

    Article  CAS  Google Scholar 

  55. Surawicz TS, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol. 1999;1(1):14–25.

    CAS  Google Scholar 

  56. Cote DJ, et al. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer. 2019;125(19):3390–400.

    Article  Google Scholar 

  57. Preston-Martin S. Descriptive epidemiology of primary tumors of the brain, cranial nerves and cranial meninges in Los Angeles County. Neuroepidemiology. 1989;8(6):283–95.

    Article  CAS  Google Scholar 

  58. Gousias K, et al. Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005–2007. Neuroepidemiology. 2009;33(2):89–95.

    Article  CAS  Google Scholar 

  59. Okamoto Y, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108(1):49–56.

    Article  Google Scholar 

  60. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977–2000. Cancer Interdiscip Int J Am Cancer Soc. 2004;101(10):2293–9.

    Google Scholar 

  61. Houben M, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989–2003. Acta Oncol. 2006;45(3):272–9.

    Article  CAS  Google Scholar 

  62. Davis FG, et al. Primary brain tumor incidence rates in four United States regions, 1985–1989: a pilot study. Neuroepidemiology. 1996;15(2):103–12.

    Article  CAS  Google Scholar 

  63. Tola MR, et al. Intracranial gliomas in Ferrara, Italy, 1976 to 1991. Acta Neurol Scand. 1994;90(5):312–7.

    Article  CAS  Google Scholar 

  64. Porter KR, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12(6):520–7.

    Article  Google Scholar 

  65. Preston-Martin S. Descriptive epidemiology of primary tumors of the spinal cord and spinal meninges in Los Angeles County, 1972–1985. Neuroepidemiology. 1990;9(2):106–11.

    Article  CAS  Google Scholar 

  66. Fuentes-Raspall R, et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. J Neurooncol. 2011;101(1):117–23.

    Article  Google Scholar 

  67. Khan S, Kambris MEK, AlShamsi ET. Epidemiology of brain tumors in the United Arab Emirates: a National Registry Cross-sectional Study. BMC Neurol. 2020;20(1):1–10.

    Article  Google Scholar 

  68. Cole GC, Wilkins PR, West RR. An epidemiological survey of primary tumours of the brain and spinal cord in South East Wales. Br J Neurosurg. 1989;3(4):487–93.

    Article  CAS  Google Scholar 

  69. Duong LM, et al. Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004–2007. Cancer. 2012;118(17):4220–7.

    Article  Google Scholar 

  70. Ahmed N, et al. Pediatric brain tumours at a tertiary care hospital in Karachi. Asian Pac J Cancer Prev. 2007;8(3):399.

    Google Scholar 

  71. Holleczek B, et al. Incidence, mortality and outcome of meningiomas: a population-based study from Germany. Cancer Epidemiol. 2019;62: 101562.

    Article  Google Scholar 

  72. Zouaoui S, et al. Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie. 2018;64(1):15–21.

    Article  CAS  Google Scholar 

  73. Werneck de Carvalho LE, et al. Central nervous system tumours profile at a referral center in the Brazilian Amazon region, 1997–2014. PLoS ONE. 2017;12(4):e0174439.

    Article  Google Scholar 

  74. Taghipour M, Razmkon A, Bakhtazad A. High prevalence of intracranial meningioma in Jewish population in Shiraz, Southern Iran. Neurosurg Q. 2010;20(2):68–70.

    Article  Google Scholar 

  75. Klaeboe L, et al. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. Int J Cancer. 2005;117(6):996–1001.

    Article  CAS  Google Scholar 

  76. Makino K, et al. Incidence of primary central nervous system germ cell tumors in childhood: a regional survey in Kumamoto prefecture in southern Japan. Pediatr Neurosurg. 2013;49(3):155–8.

    Article  Google Scholar 

  77. Johnston DL, et al. Incidence of medulloblastoma in Canadian children. J Neurooncol. 2014;120(3):575–9.

    Article  CAS  Google Scholar 

  78. Giordana MT, et al. Epidemiology of adult medulloblastoma. Int J Cancer. 1999;80(5):689–92.

    Article  CAS  Google Scholar 

  79. Jiang T, et al. Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J. 2011;124(17):2578–83.

    Google Scholar 

  80. Cordera S, et al. Epidemiology of primary intracranial tumours in NW Italy, a population based study: stable incidence in the last two decades. J Neurol. 2002;249(3):281–4.

    Article  CAS  Google Scholar 

  81. Miranda-Filho A, et al. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol. 2017;19(2):270–80.

    Google Scholar 

  82. Elia-Pasquet S, et al. Incidence of central nervous system tumors in Gironde, France. Neuroepidemiol. 2004;23(3):110–7.

    Article  Google Scholar 

  83. Rasmussen BK, et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol. 2017;135(3):571–9.

    Article  Google Scholar 

  84. Park HJ, et al. Incidence and survival of childhood cancer in Korea. Cancer Res Treat. 2016;48(3):869.

    Article  Google Scholar 

  85. Lai R. Survival of patients with adult medulloblastoma: a population-based study. Cancer. 2008;112(7):1568–74.

    Article  Google Scholar 

  86. Fleury A, et al. Descriptive epidemiology of cerebral gliomas in France. Cancer. 1997;79(6):1195–202.

    Article  CAS  Google Scholar 

  87. Rezaianzadeh A, et al. Spatio-temporal pattern of malignant neoplasm of brain in Fars province IR Iran (2011–2015): a population-based cross sectional study. Clin Epidemiol Glob Health. 2020;8(4):1006–10.

    Article  Google Scholar 

  88. Georgakis MK, et al. Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: registration improvements reveal higher incidence rates compared to the US. Eur J Cancer. 2017;86:46–58.

    Article  Google Scholar 

  89. Helseth A. The incidence of primary CNS neoplasms before and after computerized tomography availability. J Neurosurg. 1995;83(6):999–1003.

    Article  CAS  Google Scholar 

  90. Lönn S, et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer. 2004;108(3):450–5.

    Article  Google Scholar 

  91. Zhang AS, et al. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro Oncol. 2017;19(5):726–35.

    Google Scholar 

  92. Stiller C, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol. 1994;23(3):458–64.

    Article  CAS  Google Scholar 

  93. Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989–90. J Neurol Neurosurg Psychiatry. 1996;61(2):143–50.

    Article  CAS  Google Scholar 

  94. Vienne-Jumeau A, Tafani C, Ricard D. Environmental risk factors of primary brain tumors: a review. Revue neurologique. 2019;175(10):664–78.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

By the Student Research Committee of Kermanshah University of Medical Sciences. We would like to thank the esteemed officials of the center for the financial affords of this study.

Funding

By Deputy for Research and Technology, Kermanshah University of Medical Sciences (IR) (4000628). This deputy has no role in the study process.

Author information

Authors and Affiliations

  1. Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Nader Salari

  2. Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Hooman Ghasemi, Mohammad hossain Shiri & Mahvan Hemmati

  3. Department of Neurosurgery, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Reza Fatahian

  4. Medical Biology Research Centre, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Kamran Mansouri

  5. Department of Human Genetics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, 33136, USA

    Sadat Dokaneheifard

  6. Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran

    Masoud Mohammadi

Authors
  1. Nader Salari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hooman Ghasemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reza Fatahian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kamran Mansouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sadat Dokaneheifard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohammad hossain Shiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mahvan Hemmati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masoud Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NS, HGH and MSH contributed to the design MM statistical analysis participated in most of the study steps. MM and MH, and RF prepared the manuscript. KM and SD and MM and MSH, and SHSH assisted in designing the study and helped in the interpretation of the study. All authors have read and approved the content of the manuscript.

Corresponding author

Correspondence to Masoud Mohammadi.

Ethics declarations

Ethics approval and consent to participate

Ethics approval was received from the ethics committee of deputy of research and technology, Kermanshah University of Medical Sciences (IR.KUMS.REC.1400.174).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salari, N., Ghasemi, H., Fatahian, R. et al. The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis. Eur J Med Res 28, 39 (2023). https://doi.org/10.1186/s40001-023-01011-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40001-023-01011-y

Keywords

European Journal of Medical Research

ISSN: 2047-783X

Contact us